FK949E
Sponsors
Astellas Pharma Inc
Conditions
Bipolar DepressionBipolar DisorderElderlyHealthyMajor Depressive DisorderMajor Depressive Disorder PatientsPharmacokinetics of QuetiapinePlasma Concentration Change of Quetiapine
Phase 1
Study to Evaluate the Effect of Food Intake on the Plasma Concentration Changes of Quetiapine After Oral Administration of FK949E in Healthy Volunteers
CompletedNCT01871987
Start: 2009-06-30End: 2009-08-31Updated: 2017-03-09
Study to Evaluate Safety and Tolerability of FK949E in Patients With Major Depressive Disorder
CompletedNCT01871974
Start: 2009-05-31End: 2010-03-31Updated: 2017-02-16
Study to Evaluate Safety and Tolerability of FK949E in Elderly Patients With Major Depressive Disorder
CompletedNCT01903200
Start: 2010-02-28End: 2011-09-30Updated: 2017-02-16
Study to Evaluate the Effect of Multiple-dose of Fluvoxamine on the Plasma Concentration of Quetiapine (FK949E) in Healthy Male Volunteers
CompletedNCT01908296
Start: 2011-07-31End: 2011-08-31Updated: 2017-02-16
Comparison of Plasma Concentration Changes Between Two Types of Tablets of FK949E Administration to Patients With Major Depressive Disorder
CompletedNCT01919008
Start: 2012-03-26End: 2012-06-22Updated: 2024-10-31
Oral Multiple-dose Study in Patients With Major Depressive Disorder
CompletedNCT01924520
Start: 2010-11-30End: 2011-05-31Updated: 2017-02-16
Phase 2
Phase 3
Long-term Study of FK949E in Elderly Bipolar Disorder Patients
CompletedNCT01737268
Start: 2012-10-29End: 2016-06-29Updated: 2024-11-19
Study to Evaluate the Effects of Switching Different Strength Forms of FK949E in Bipolar Disorder Patients With Major Depressive Episodes
CompletedNCT02362412
Start: 2015-02-18End: 2016-02-06Updated: 2024-11-15